HOOKIPA PHARMA INC (HOOK)

US43906K1007 - Common Stock

0.7204  +0 (+0.19%)

After market: 0.71 -0.01 (-1.44%)

News Image
6 days ago - InvestorPlace

HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023

HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

News Image
6 days ago - BusinessInsider

HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOKIPA Pharma (NASDAQ:HOOK) just reported results for the fourth quarter of 20...

News Image
6 days ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in...

News Image
22 days ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...

News Image
2 months ago - Seeking Alpha

Hookipa to cut 30% of workforce in wake of Roche deal termination (NASDAQ:HOOK)

Hookipa (HOOK) stock fell 15% after the company said it was cutting 30% of its workforce amid news Roche had terminated a collaboration deal for the drug HB-700. Read more here.

News Image
2 months ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...

News Image
2 months ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...

News Image
3 months ago - Seeking Alpha

HOOKIPA Pharma files to sell 15M shares for holders (NASDAQ:HOOK)

HOOKIPA Pharma files a prospectus for the proposed resale of 15M shares of common stock by a selling stockholder. This is not an offer to sell securities.

News Image
3 months ago - InvestorPlace

Why Is Polished.com (POL) Stock Down 38% Today?

Polished.com stock is falling on Thursday as investors in POL react to the company's shares undergoing an extreme rally on Wednesday!

News Image
3 months ago - InvestorPlace

Why Is Brenmiller Energy (BNRG) Stock Up Today?

Brenmiller Energy stock is rising on Thursday as investors celebrate shares of BNRG regaining compliance with listing standards.

News Image
3 months ago - InvestorPlace

Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?

Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.

News Image
3 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

News Image
3 months ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023,...

News Image
4 months ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for...

News Image
5 months ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+...

News Image
5 months ago - HOOKIPA Pharma Inc.

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+...